Patient access to treatment remains poor. For the second year in a row, patients with chronic conditions rated health plan ...

The CDMO’s new services at its Hopewell, NJ facility delivers scalable, phase-appropriate production, in-house quality ...

In the final part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

This episode of Pharma Pulse explores the FDA’s new proactive quality review initiative for drug manufacturing, GSK’s $370 ...

From rethinking launch price logic to implementing rebate-aware modeling and patient-first access programs, this installment ...

The GSK Flovent example highlights the consequences for patients and pharma of the decision to eliminate the Medicaid rebate cap.